Beijing Bohui Innovation Biotechnology Co., Ltd. signed a share transfer agreement to acquire 50% stake in Changzhou Linghang Quantum Biomedical Technology Co., Ltd. from Gao Sheng, Tu Mingyu and Yang Wanbin for CNY 24 million.
September 12, 2020
Share
Beijing Bohui Innovation Biotechnology Co., Ltd. (SZSE:300318) signed a share transfer agreement to acquire 50% stake in Changzhou Linghang Quantum Biomedical Technology Co., Ltd. from Gao Sheng, Tu Mingyu and Yang Wanbin for CNY 24 million on September 12, 2020. Simultaneously, Beijing Bohui Innovation Biotechnology Co., Ltd. agreed to carry out Changzhou Linghang Quantum Biomedical Technology Co., Ltd's capital increase of CNY 25 million following which Beijing Bohui Innovation Biotechnology Co., Ltd. will hold a total of 67.12% stake in Changzhou Linghang Quantum Biomedical Technology Co., Ltd. For the year ending December 31, 2019, Changzhou Linghang Quantum Biomedical Technology Co., Ltd. reported total assets of CNY 0.94 million, net assets of CNY 0.90 million, revenue of CNY 0.15 million and net loss of CNY 0.96 million. The transaction has been approved by the General managers meeting of Beijing Bohui Innovation Biotechnology. The transaction does not need approval of Board of Directors and shareholders of Beijing Bohui Innovation Biotechnology.
Beijing Bohui Innovation Biotechnology Group Co Ltd, formerly Beijing Bohui Innovation Biotechnology Co Ltd is a China-based company mainly engaged in testing and biological products. The testing business products are divided into testing instruments and testing reagents, including human papillomavirus (HPV) testing products, trace element testing products, mass spectrometry related testing products, and others. The biological products mainly cover three categories: albumin, immunoglobulin and human coagulation factors, including human serum albumin, human immunoglobulin, intravenous human immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, human prothrombin complex, and others. The Company mainly operates its business in the domestic market.
Beijing Bohui Innovation Biotechnology Co., Ltd. signed a share transfer agreement to acquire 50% stake in Changzhou Linghang Quantum Biomedical Technology Co., Ltd. from Gao Sheng, Tu Mingyu and Yang Wanbin for CNY 24 million.